Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has a higher price-to-earnings ratio of 12.97x compared to its average ratio. REGN has 36-month beta value of 0.31. Analysts have mixed views on the stock, with 14 analysts rating it as a “buy,” 6 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for REGN is 104.06M, and currently, short sellers hold a 2.59% ratio of that float. The average trading volume of REGN on June 20, 2025 was 1.33M shares.
REGN) stock’s latest price update
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) has experienced a decline in its stock price by -0.76 compared to its previous closing price of 513.58. However, the company has seen a fall of -2.33% in its stock price over the last five trading days. zacks.com reported 2025-06-20 that SNY and REGN’s Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.
REGN’s Market Performance
REGN’s stock has fallen by -2.33% in the past week, with a monthly drop of -17.10% and a quarterly drop of -23.08%. The volatility ratio for the week is 1.91% while the volatility levels for the last 30 days are 5.09% for Regeneron Pharmaceuticals, Inc The simple moving average for the past 20 days is -3.67% for REGN’s stock, with a -31.53% simple moving average for the past 200 days.
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with Wells Fargo repeating the rating for REGN by listing it as a “Equal Weight.” The predicted price for REGN in the upcoming period, according to Wells Fargo is $580 based on the research report published on May 30, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see REGN reach a price target of $662. The rating they have provided for REGN stocks is “Sector Perform” according to the report published on May 30th, 2025.
Citigroup gave a rating of “Buy” to REGN, setting the target price at $700 in the report published on May 14th of the current year.
REGN Trading at -8.75% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.92% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from McCourt Marion, who sale 1,000 shares at the price of $844.61 back on Nov 01 ’24. After this action, McCourt Marion now owns 12,931 shares of Regeneron Pharmaceuticals, Inc, valued at $844,610 using the latest closing price.
MARION E MCCOURT, the Officer of Regeneron Pharmaceuticals, Inc, proposed sale 1,000 shares at $844.61 during a trade that took place back on Nov 01 ’24, which means that MARION E MCCOURT is holding shares at $844,610 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.85 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc stands at 0.32. The total capital return value is set at 0.11. Equity return is now at value 15.96, with 12.51 for asset returns.
Based on Regeneron Pharmaceuticals, Inc (REGN), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.46. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 98.59.
Currently, EBITDA for the company is 5.32 billion with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 3.82. The receivables turnover for the company is 2.53for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.
Conclusion
To put it simply, Regeneron Pharmaceuticals, Inc (REGN) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
